Category - News


Interview – Accera next up in Alzheimer’s disease

By: Jonathan Gardner  Date: November 25, 2016 Lilly’s solanezumab might have blown up and erased $11bn in market capitalisation this week, but the potential reward from delivering a disease-modifying drug in Alzheimer’s disease is too attractive for many companies to ignore. Colorado-based Accera could have the next major data point in the space: readout of an early phase …


So long to Sola; Lilly bloom’s hope withers big pharma continues to ‘Chase’ AD dream

By Randy Osborne Last week’s phase III blowup of Eli Lilly and Co.’s solanezumab(sola) in Alzheimer’s disease (AD) struck up a familiar dirge in the failure-strewn space, and set experts to debating – again, still – the amyloid beta hypothesis, as companies that have chosen to pursue other routes continued to laud their approaches and …


Nestlé Wants to Sell You Both Sugary Snacks and Diabetes Pills

By Matthew Campbell & Corinne Gretler Nestlé is by far the largest food company in the world. Its 335,000 employees produce more than 2,000 brands, manufactured in 436 factories across 85 countries. It’s Europe’s most valuable corporation, worth $240 billion, comfortably more than oil giant Royal Dutch Shell. Among the world’s 195 nations, it sells …


Broomfield Biotech Firm Accera Moves to Boulder

by Joshua Lindenstein on April 27, 2016 BOULDER — Clinical-stage biotech firm Accera, which is developing a therapy to treat Alzheimer’s Disease, has moved from Broomfield to Boulder to become part of the latter’s bustling life-sciences scene and cash in Boulder’s international reputation as a startup haven. Read full article at:


Bioscience roundtable: Attracting development capital, talent top of mind in Colorado

by Joshua Lindenstein on April 20, 2016 BOULDER — Venture-capital investment in life-science and biotechnology companies nationwide, according to MoneyTree data dating back to 1995, hit its highest level ever during that period in 2015. Read full article at: